Immix Biopharma (IMMX) provided an update on its lead asset NXC-201 at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, highlighting accelerating clinical progress for its BCMA-directed CAR T therapy in AL amyloidosis.
Complete response rates for NXC-201 have climbed through ongoing evaluation: 70% at ASCO 2023, rising to 75% at ASH 2023. Among the first 20 patients in the study, 19 achieved complete response, yielding a 95% rate. The full registrational population comprises 45 patients—20 with longer follow-up and 25 more recently enrolled with shorter observation periods. Top-line data from the NEXICART-2 Phase II study, which evaluates NXC-201 in second-line relapsed or refractory AL amyloidosis, is expected in late September 2024.
The company plans to file a Biologics License Application in March 2025, a timeline that allows for a one-year follow-up across all patients. Immix has received Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Orphan Drug designations from the FDA for NXC-201, which is licensed from Hadassah Medical Center and incorporates learnings from Dr. Steven Rosenberg's laboratory at the U.S. National Cancer Institute.
AL amyloidosis affects approximately 5,000 patients diagnosed annually in the United States. The current standard of care, a four-drug DARZALEX regimen approved in 2021, produces complete responses in roughly 50% of patients, and about two-thirds eventually require additional treatment. No approved next-line therapy exists for patients who fail the four-drug combination. Competing bispecific therapies carry infection rates of 70–80% and hospitalization rates up to 30%.
NXC-201 features what Immix describes as a markedly improved safety profile, with a median cytokine release syndrome duration of just one day—four to eight times shorter than approved CAR T products. The therapy addresses a clinical challenge in AL amyloidosis where heart failure requires fluid removal while kidney failure demands hydration. Design elements include a specific CD3 domain, a stiffer CD8 hinge region, and a proprietary binder that Immix calls a "biological filter."
Immix has initiated a Phase III frontline study comparing NXC-201 head-to-head against the four-drug DARZALEX regimen, with complete response rate as the primary endpoint. Co-founder Gabriel described the treatment as a "liberating therapy" capable of being delivered in "24 hours, not 24 months." CEO Akhmed Rachman noted that key opinion leaders have expressed strong enthusiasm, citing a hematologist's remark at ASH: "Why aren't we dosing anything else in this disease?"
Commercial infrastructure is planned to initially target approximately 60 AL referral centers. Immix projects its current cash position will fund all planned activities through mid-2028. AbbVie disclosed a competing frontline trial in late August 2024.
Shares of Immix Biopharma closed regular-session trading at $12.21, up 0.58%, before slipping to $12.00 in after-hours trading. The stock has dropped 12% over the past week but remains up 134% year-to-date and 481% over the past year.
